Pledge Therapeutics

Edit info

Founded: 2021

Location: Canton, MA

Employee range: 11 - 50

Clinical stage: RD

Therapy area: viruses, immuno-oncology

Drug types: INF, ONC

Lead product: Undisclosed

Funding: $6M Jul 2023; $18.5M total Jul 2023

pledge-tx.com

linkedin.com

job board

Drug notes:

Undisclosed RD bacterial infections; undisclosed RD COVID-19; undisclosed RD immuno-oncology

About:

Pledge Therapeutics is using rational design to tackle the most challenging drug targets in modern medicine. There are many current known molecular targets for disease that have been unsuccessfully targeted with drugs. Pledge is solving this by developing small molecule drugs that demonstrate target engagement and deliver a profound disease-modifying effect. This involves the use of cutting-edge biophysical and orthogonal technologies and solving high-resolution structures of protein-drug complexes. Pledge’s current portfolio consists of first-in-class immune-oncology and antiviral medicinal assets to treat several life-threatening diseases.